Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.

CONCLUSIONS: Patients with EGFR 19 del exhibit longer PFS and higher ORR compared with those with L858R mutations. Whether the heterogeneity of tumors with EGFR 19 del and L858R mutations contribute to a therapeutic response difference needs further investigation. PMID: 27001083 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/27001083?dopt=Abstract

Source: Chinese Journal of Cancer - March 25, 2016 Category: Cancer & Oncology Tags: Chin J Cancer Source Type: research